A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
D.R. Horton (NYSE: DHI), the largest U.S. homebuilder by volume, has taken investors on a roller-coaster ride over the last ...
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...
We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...
Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results